Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Active not recruiting 5Recruiting 2Terminated 1Completed 1Available 1

Sponsor Class

INDUSTRY 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 3Sarcoma 2

Conditions

Multiple Myeloma 3Desmoid Tumors 2

Interventions

Specimen Handling 218Magnetic Resonance Spectroscopy 194pembrolizumab 185Carboplatin 160Biopsy 129Cisplatin 128Nivolumab 119Paclitaxel 107Cyclophosphamide 104Radiotherapy 99Gemcitabine 96Dexamethasone 86durvalumab 83atezolizumab 70Rituximab 66Radiation 64Lenalidomide 64Doxorubicin 63Pemetrexed 61Bevacizumab 58Etoposide 56Docetaxel 56olaparib 50Ipilimumab 49Fluorouracil 48Taxes 47Prednisone 47Oxaliplatin 46Vincristine 45Cytarabine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × nirogacestat × 90 days × Clear all
NCT04722146 2026-06-05

MajesTEC-2

Janssen Research & Development, LLC

Phase 1 Active not recruiting
140 enrolled
Plasma cell

Multiple Myeloma

NCT07170644 2026-05-08

A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Active not recruiting
20 enrolled
Sarcoma

Desmoid Tumors

NCT04126200 2026-05-06

DREAMM 5

GlaxoSmithKline

Phase 1/2 Active not recruiting
208 enrolled 5 charts
Plasma cell

Multiple Myeloma

NCT07084896 2026-05-06

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

GlaxoSmithKline

Phase 1/2 Active not recruiting
106 enrolled 32 charts
Plasma cell

Multiple Myeloma

NCT04195399 2026-04-15

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

Children's Oncology Group

Phase 2 Active not recruiting
31 enrolled
Sarcoma

Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡